Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017034877) CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2017/034877 International Application No.: PCT/US2016/047335
Publication Date: 02.03.2017 International Filing Date: 17.08.2016
IPC:
A61K 31/47 (2006.01) ,A61K 31/4704 (2006.01) ,A61K 31/4706 (2006.01) ,C07D 215/42 (2006.01) ,C07D 215/44 (2006.01)
[IPC code unknown for A61K 31/47][IPC code unknown for A61K 31/4704][IPC code unknown for A61K 31/4706][IPC code unknown for C07D 215/42][IPC code unknown for C07D 215/44]
Applicants:
MACIELAG, Mark J. [US/US]; US (US)
JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30 B-2340 Beerse, BE
Inventors:
MACIELAG, Mark J.; US
ZHANG, Yue-Mei; US
GRECO, Michael N.; US
SPRINGER, Barry A.; US
MURRAY, William V.; US
Agent:
DEBERARDINE, Robert; US
DODD, Thomas; US
Priority Data:
62/210,48127.08.2015US
Title (EN) CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
(FR) DÉRIVÉS DE QUINOLONE ET DE QUINOLÉINE CHIMIQUEMENT MODIFIÉS UTILES EN TANT QU'AGONISTES INVERSES DE CB-1
Abstract:
(EN) Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group " X=Y", ring A, R10, R11, R30, W, and t are defined herein.
(FR) L'invention concerne des composés, des compositions et des méthodes de traitement de troubles qui sont affectés par la modulation du récepteur CB1. Ces composés sont représentés par la formule (l) dans laquelle R1, R2, R3, L1, n, v, r, w, et g sont définis dans la description, et, en outre, représentés par la formule (II) dans laquelle le groupe "X = Y ", le cycle A, R10, R11, R30, W, et t sont tels que définis dans la description.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)